CDIO
Cardio Diagnostics Holdings, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.86
+1.64%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 14.4K | 14.8K | 34.9K | 17.1K | 950.00 |
| Cost of Revenue | 94.7K | — | — | — | — |
| Gross Profit | (80.2K) | 14.8K | 34.9K | 17.1K | 950.00 |
| Operating Expenses | |||||
| R&D Expense | 768.6K | 641.2K | 228.0K | 145.2K | 40.4K |
| SG&A Expense | 5.7M | 5.8M | 8.2M | 7.1M | 4.5M |
| General & Admin Expense | 4.8M | 5.0M | 6.9M | 6.9M | 4.4M |
| Selling & Marketing Expense | 900.9K | 766.9K | 1.2M | 158.5K | 92.7K |
| Other Expenses | (72.2K) | 65.2K | 19.7K | 19.2K | 16.0K |
| Total Operating Expenses | 6.4M | 6.5M | 8.4M | 7.3M | 4.5M |
| Cost and Expenses | 6.5M | 6.5M | 8.4M | 7.3M | 4.5M |
| Operating Income (EBIT) | (6.5M) | (6.5M) | (8.4M) | (7.2M) | (4.5M) |
| Non-Operating | |||||
| Interest Income | 572.00 | 712.00 | 1.1K | 1.1K | — |
| Interest Expense | 12.3K | 14.8K | 18.6K | 6.7M | — |
| Net Interest Income | (11.7K) | (14.1K) | (17.6K) | (6.7M) | — |
| Other Non-Op Income/Expense | (11.7K) | (14.1K) | (17.6K) | (1.1M) | (112.5K) |
| Non-Operating Income (excl Interest) | (572.00) | (712.00) | (1.1K) | (5.6M) | 112.5K |
| EBT (Pre-Tax Income) | (6.5M) | (6.5M) | (8.4M) | (8.4M) | (4.7M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (6.5M) | (6.5M) | (8.4M) | (8.4M) | (4.7M) |
| Earnings from Cont. Ops | (6.5M) | (6.5M) | (8.4M) | (8.4M) | (4.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (6.5M) | (6.5M) | (8.4M) | (8.4M) | (4.7M) |
| Per Share | |||||
| Basic EPS | ($2.92) | ($3.71) | ($9.30) | ($19.80) | ($45.30) |
| Diluted EPS | ($2.92) | ($3.71) | ($9.30) | ($19.80) | ($45.30) |
| Revenue Per Share | $0.00 | $0.01 | $0.00 | $0.04 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 3.0M | 1.8M | 26.9M | 422837 | 3.1M |
| Diluted Shares Outstanding | 3.0M | 1.8M | 26.9M | 422837 | 3.1M |
| Profitability Metrics | |||||
| EBITDA | (6.2M) | (6.1M) | (8.1M) | (1.5M) | (4.6M) |
| D&A | 283.9K | 398.1K | 276.3K | 111.6K | 16.0K |
| EBIT | (6.5M) | (6.5M) | (8.4M) | (1.6M) | (4.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026